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Background
The use of doxorubicin (DOX), a potent chemotherapeu-
tic agent, is limited by cardiotoxicity, leading to conges-
tive heart failure in up to 5% of DOX-treated patients.
Dysfunctional cyclic guanosine 3’, 5’-monophosphate
(cGMP) signaling has been implicated in various cardio-
vascular diseases, including cardiotoxicity associated with
DOX administration. We tested the hypothesis that
cGMP generated by soluble guanylate cyclase (sGC), the
target for clinically available pharmacological agents that
enhance cGMP levels (e.g. riociguat), protects against
DOX-induced cardiomyopathy.
Methods and results
Nitric oxide (NO)-stimulated sGC enzyme activity was
lower in myocardial tissue extracts from wild-type (WT)
mice exposed to DOX (20 mg/kg, IP, 24h), than from
vehicle-treated WT mice (20.4±2.1 vs. 25.7±1.4 pmol
cGMP/mg protein/min, respectively, n=10 for both,
P<0.05). To investigate whether decreased cardiac cGMP
synthesis by sGC contributes to DOX-induced cardio-
toxicity, we studied mice with a cardiomyocyte-specific
deficiency in the a1-subunit of sGC (sGCa1-/-), obtained
using a Cre-lox conditional knockout strategy. At base-
line, left ventricular (LV) dimensions and function,
assessed via transthoracic echocardiography (TTE), were
similar in sGCa1-/- and WT mice. After 12 weeks DOX
(2 mg/kg/week, IP), TTE and invasive hemodynamic
measurements revealed greater LV dysfunction and dila-
tation in sGCa1-/- than in WT mice (Table 1).
In a second mouse model, myocardial sGC activity
was reduced by cardiomyocyte-specific expression of a
dominant-negative sGCa1 mutant (DNsGCa1tg/+) in an
inducible manner (Tet-Off). Withdrawing tetracycline
from the diet resulted in a ~50% reduction of cardiac
sGC activity (18.6±2.6 vs. 32.0±5.4 pmol cGMP/mg pro-
tein/min in 8 DNsGCa1tg/+and 8 WT mice, respectively,
P<0.05). At baseline, LV dimensions and function were
similar in DNsGCa1tg/+and WT mice. Chronic DOX
treatment resulted in greater LV systolic dysfunction
and dilatation in DNsGCa1tg/+ than in WT mice after 8
and 12 weeks (TTE, data not shown). Importantly, LV
dysfunction observed in DNsGCa1tg/+exposed to DOX
for 12 weeks could be attenuated by re-adding tetracy-
cline to the diet [thereby suppressing expression of the
dominant negative sGCa1 mutant and de-repressing
endogenous sGC activity] after 8 weeks of DOX admin-
istration: fractional shortening improved significantly in
DNsGCa1tg/+ mice by 16 weeks (28±1% at 8 weeks vs.
35±1% at 16 weeks, n=17 and 20, respectively, P <0.05).
Conclusions
Reduced myocardial sGC activity results in increased
LV dysfunction and dilatation in DOX-treated mice.
Pharmacological stimulation of sGC may represent a pro-
mising therapeutic approach to tackle DOX-associated
cardiotoxicity.
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Table 1. DOX-induced LV dysfunction and remodeling after 12 weeks chronic treatment is greater in sGCa1-/- than WT
mice
Echocardiography WT + saline (n=7) sGCa1-/- + saline (n=6) WT + DOX (n=12) sGCa1-/- + DOX (n=11)
LVIDS (mm) 1.3±0.1 1.3±0.0 1.7±0.1† 2.0±0.1†*
LVIDD (mm) 3.0±0.0 3.0±0.0 3.2±0.1† 3.3±0.0†
FS (%) 57±1 57±1 48±2† 40±1†*
HR (bpm) 531±13 505±18 428±17† 426±18†
Hemodynamic measurements WT + saline (n=6) sGCa1-/- + saline (n=5) WT + DOX (n=12) sGCa1-/- + DOX (n=9)
ESV (μl) 19±1 19±1 26±3† 37±3†*
EDV (μl) 43±2 41±2 51±2† 58±2†*
EF (%) 60±2 58±3 55±4 42±3†*
dP/dtmax (mmHg/s) 13,499±1,433 11,995±601 13,503±678 10,386±875*
dP/dtmin (mmHg/s) -12,053±1,809 -11,420±950 -13,531±846 -10,943±940¶
Tau (ms) 5.1±0.1 4.9±0.2 5.6±0.2† 6.3±0.3†¶
PRSW 83±9 84±6 70±9 49±7†¶
Ees (mmHg/μl) 6.3±1.2 7.3±1.4 4.0±0.8† 2.3±0.3†¶
EDPVR (mmHg/μl) 0.21±0.03 0.18±0.02 0.16±0.02 0.19±0.02
HR (bpm) 576±8 614±12 528±9† 530±14†*
LVIDS indicates left ventricular internal diameter at end-systole; LVIDD, left ventricular internal diameter at end-diastole; FS, fractional shortening; HR, heart rate;
ESV, end-systolic volume; EDV, end-diastolic volume; EF, ejection fraction; dP/dtmax and dP/dtmin, maximum and minimum of the first derivative of LV pressure
over time; Tau, time constant for isovolumic relaxation; PRSW, pre-load recruitable stroke work; Ees, end-systolic elastance; and EDPVR, end-diastolic pressure
volume relationship. Values are presented as mean±SEM.
† P<0.05 vs. saline,
* P<0.05 vs. WT + DOX, and
¶ P≤0.10 vs. WT + DOX.
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